** Shares of medical device maker Embecta EMBC.O rise 2% to $8.99 premarket

** Co says it will buy privately held Owen Mumford in a deal worth up to 150 million pounds ($199.10 million), expanding into drug‑delivery devices beyond diabetes

** Co will pay 100 million pounds in cash upfront, with up to 50 million pounds tied to sales of Owen Mumford's Aidaptus auto-injector platform over three years - EMBC

** Owen Mumford makes auto-injectors and self-injection devices used to deliver drugs for conditions such as obesity, autoimmune diseases and allergies, co says

** Says the deal will help diversify revenue and support growth using its global sales network

** Transaction is expected to close in fiscal Q3 2026, subject to regulatory approvals; deal funded through borrowings - EMBC

** Shares down ~42% in 2025

($1 = 0.7534 pounds)